Search

ImmunityBio Inc

Gesloten

SectorGezondheidszorg

8.44 -0.59

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.25

Max

8.86

Belangrijke statistieken

By Trading Economics

Inkomsten

-230M

-863M

Verkoop

7M

51M

EPS

-0.08

Winstmarge

-1,684.596

Werknemers

684

EBITDA

378M

-222M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+53.3% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

8.9B

Vorige openingsprijs

9.03

Vorige sluitingsprijs

8.44

Nieuwssentiment

By Acuity

50%

50%

111 / 339 Rangschikking in Healthcare

ImmunityBio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2026, 20:02 UTC

Social Media

ImmunityBio Inc is trading sharply higher, nearing $12, amid notable social media attention and unusually high market volume, despite a slight pullback earlier in the session.

16 sep 2026, 20:10 UTC

Immunitybio Inc shares are declining, remaining below their 20-day moving average, following a notable early high in Wednesday's trading session.

15 sep 2026, 23:01 UTC

Immunitybio Inc shares are lower in after-market trading. Broader market sentiment may be affected by a significant decline in the New York Empire State Manufacturing Index.

14 sep 2026, 20:08 UTC

Social Media
News

ImmunityBio Inc is gaining as it participates in key cancer conferences this week and files a patent for Anktiva to enhance immune response.

11 sep 2026, 20:03 UTC

News

ImmunityBio Inc is higher as it prepares for key presentations at upcoming conferences and highlights potential uses for Anktiva in cancer treatment.

10 sep 2026, 19:36 UTC

News

ImmunityBio shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential corporate wrongdoing targeting prior investors.

9 sep 2026, 23:01 UTC

Immunitybio Inc. shares declined after hours, reflecting a notable drop from an earlier session high amid no specific company news identified.

8 sep 2026, 23:16 UTC

Immunitybio Inc shares are lower in after-market hours, with no specific news identified. Broader market weakness is attributed to geopolitical tensions in the Middle East.

3 sep 2026, 19:26 UTC

Immunitybio Inc's shares are higher today, reflecting positive market sentiment amid declining Treasury yields and easing labor market concerns.

2 sep 2026, 23:06 UTC

Immunitybio Inc shares are lower in after-market trading, with no specific news identified. The broader market reacted to a weaker ADP payrolls report.

31 aug 2026, 20:07 UTC

Immunitybio Inc shares are lower amid broader market pressures and rising bond yields following comments from Warsh at the Jackson Hole Economic Symposium.

29 aug 2026, 00:01 UTC

Immunitybio Inc shares are higher in after-market trading, though no specific news was identified for the price movement. The stock remains near its one-month range high.

28 aug 2026, 20:02 UTC

Immunitybio Inc. shares are lower today, reflecting broader market trends amid rising U.S. Treasury yields. The stock remains above its 20-day moving average.

27 aug 2026, 23:01 UTC

Immunitybio Inc. traded roughly flat after-market, despite earlier gains. Broader market trends reflected mixed trading and inflation concerns ahead of a key Fed speech.

26 aug 2026, 19:16 UTC

News
Social Media

ImmunityBio Inc. shares are trading higher as institutional interest grows, with Virginia Retirement System holding 74,500 shares and promising trial data for Anktiva.

24 aug 2026, 20:06 UTC

Immunitybio Inc's shares are lower today, continuing a decline over three trading days. Broader market sentiment is impacted by rising oil prices and geopolitical tensions.

21 aug 2026, 19:16 UTC

Immunitybio Inc. shares are lower today amid rising crude oil prices and geopolitical tensions, despite remaining above their 20-day moving average.

20 aug 2026, 23:06 UTC

Immunitybio Inc. shares are lower in after-market trading, declining since Thursday's close. The asset remains above its 20-day moving average.

19 aug 2026, 19:26 UTC

Social Media

Immunitybio Inc shares are higher Wednesday, buoyed by social media discussions anticipating prices between $8 and $12. The stock remains above its 20-day moving average.

18 aug 2026, 23:06 UTC

Immunitybio Inc shares are lower in after-market hours, with no specific news identified. Broader market conditions reflect a decline in U.S. stocks.

14 aug 2026, 19:36 UTC

Immunitybio shares are lower amid broader market sentiment following a reported decline in retail sales, raising concerns about consumer demand and economic health.

10 aug 2026, 19:16 UTC

News

ImmunityBio Inc. appoints Dr. Jim Yong Kim as Vice Chairman. Shares are lower today amid broader market pressure from a U.S. jobs report.

7 aug 2026, 23:06 UTC

Immunitybio Inc's shares are lower in after-market hours, with no specific news driving the decline. The stock remains above its 20-day moving average.

6 aug 2026, 23:11 UTC

Immunitybio Inc's shares are higher in after-market trading, reflecting a slight increase since Thursday's close, though still below the 20-day moving average.

5 aug 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 aug 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 aug 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 aug 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 jul 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 jul 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

Peer Vergelijking

Prijswijziging

ImmunityBio Inc Prognose

Koersdoel

By TipRanks

53.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13 USD  53.3%

Hoogste 15 USD

Laagste 12 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor ImmunityBio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Sentiment

By Acuity

111 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.